Lipids and stroke: A paradox resolved

Archives of Neurology

Volumn 53, Issue 4, 1996, Pages 303-308

  Hachinski, Vladimir ^a,b   Graffagnino, Carmelo ^c   Beaudry, Michel ^d   Bernier, Gilles ^e   Buck, Carol ^b   Donner, Allan ^b   Spence, J David ^a   Doig, Gordon ^b   Wolfe, Bernard M J ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CHICOUTIMI HOSPITAL   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; FERRITIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029926802     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550040031011     Document Type: Article

References (71)

1. Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis, a review. Stroke. 1988;19:423-430.
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousian S, Kannel WB Incidence of coronary heart disease and lipoprotein cholesterol levels JAMA 1986;256:2835-2838
3. Miller GJ, Miller NE Plasma high-density lipoprotein concentration and development of ischemic heart disease. Lancet 1975;1:16-19
4. Gordon T, Castelli WP, Hjorland MC, Kannel WB, Dawber TR High density lipoproteins as a protective factor against coronary heart disease. Am J Med. 1977;61 707-716.
5. Senti M, Pedro-Botet J, Nogues X, Rubies-Prat J, Vidal-Barraquer F Lipoprotein profile in men with peripheral vascular disease: role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992;85:30-36.
6. Krauss RM Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987;113:578-582.
7. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease Circulation. 1987;75:124-130.
8. Austin MA, King MC, Vranizan KM, Krauss RM Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
9. Rhoads GA, Feinleib M Serum triglyceride and risk of coronary heart disease, stroke and total mortality in Japanese-American men. Atherosclerosis. 1983;3 316-322.
10. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth O. Serum cholesterol, blood pressure, and mortality implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
11. Keys A Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease Cambridge, Mass. Harvard University Press; 1980.
12. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease and death: the Framingham Study. Arch Intern Med. 1981;141:1128-1131
13. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease. N Engl J Med. 1983;309:385-389.
14. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovitch PO Jr. Association of coronary atherosclerosis with hyperapolipoprotienemia (increased protein but normal cholesterol levels in human plasma low density [beta] lipoproteins). Proc Natl Acad Sci U S A. 1980;77:604-608.
15. Ordovas JM, Schaefer EJ, Sadem D, et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med. 1986;314:671-677.
16. Juergens JL, Bernatz PE. Atherosclerosis of the extremities In: Juergens JL, Spittell JF Jr, Fairbairn II, eds. Peripheral Vascular Diseases. 5th ed Philadelphia, Pa: WB Saunders Co, 1980 253-293.
17. Fuster V, Kottke BA, Juergen JL. Atherosclerosis. In: Juergens JL, Spittell JF Jr, Fairbairn II, eds. Peripheral Vascular Diseases. 5th ed. Philadelphia, Pa: WB Saunders Co; 1980:219-235.
18. Salonen JT, Nyssonen K, Korpela H, Tuomilehto JT, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men Circulation 1992;86 803-811
19. Brewer HB, Gregg RE, Hoeg JM, Fojo SS Apolipoproteins and lipoproteins in human plasma a review Clin Chem. 1988;34:B4-B8.
20. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis. 1988;8:1-21
21. Gregg RE, Zech LA, Gabelli C, Brewer HB. Apolipoprotein modulates the metabolism of apolipoprotein B containing lipoproteins by multiple mechanisms. In. Steinmetz A, Kaffarnik H, Schneider J, eds. Cholesterol Transport Systems and Their Relation to Atherosclerosis. Berlin, Germany: Springer-Verlag; 1989:11-21.
22. Frohlich J Hyperlipoproteinemias Ann R Coll Phys Surg Can. 1984;17-209-214.
23. Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis: lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med. 1983;309:288-296.
24. Karathanasis SK, Norum RA, Zannis VI, Breslow JL. An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis. Nature 1983;301:718-720
25. Thompson G, Soutar A. Genetic polymorphisms and plasma lipoproteins. Nature. 1983;301:658.
26. Morrison JA, Namboodiri K, Green P, Martin J, Glueck CJ. Familial aggregation of lipids and lipoproteins and early identification of dyslipoproteinemia. the Collaborative Lipid Research Clinics Family Study JAMA. 1983;250:1860-1868
27. Gotto AMJ. Apolipoprotein C-II deficiency revisited. N Engl J Med 1984;310: 1664-1665.
28. Connelly PW, Maguire GF, Hofmann T, Little JA. Structure of apolipoprotein C-II Toronto, a nonfunctional human apolipoprotein Proc Natl Acad Sci USA 1987;84:270-273
29. Austin MA, Kraus RM. Genetic control of low-density lipoprotein subclasses Lancet 1986;2 592-595
30. Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich P Familial aggregation and early expression of hyperapobetalipoproteinemia Am J Cardiol 1985;55:291-295.
31. Eto M, Watanabe K, Ischii K. A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application Clin Chim Acta. 1985;149:21-28.
32. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest. 1955; 34:1345-1353.
33. Warnick GR, Albers JJ A comprehensive evaluation of the heparin-manganese procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
34. Friedwald WT, Levy RS, Fredockson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502
35. Wolf PA, Belanger AJ, D'Agostino RB Management of risk factors Neurol Clin. 1992;10:177-191.
36. Spence JD. Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke 1986;17:808-810
37. Iso H, Jacobs DR, Wentworth D, Neaton J, Cohen JD, for the MRFIT Research Group. Serum cholesterol levels and 6-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910
38. Kagan A, Popper JS, Rhoads GG, Yano K. Dietary and other risk factors for stroke in Hawaiian Japanese men. Stroke. 1985;16:34-38.
39. Konishi M, Terao A, Doi M. Osmotic resistance and cholesterol content of the erythrocyte membrane in cerebral hemorrhage. Igaku Ayumi. 1982;120:30-32.
40. Mendez I, Hachinski VC, Wolfe BM. Serum lipids after stroke. Can J Neurol Sci 1985;12:210. Abstract.
41. Mendez I, Hachinski VC, Wolfe BM. Serum lipids after stroke. Neurology. 1987; 37:507-511.
42. Hollanders FD, Shafar J, Burton P. Serum lipid changes following the completed stroke syndrome. Postgrad Med J. 1975;51:386-389.
43. Szatrowski TP, Peterson AVJ, Shimizu Y, et al. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort J Chronic Dis. 1984; 37:569-584.
44. Salonen JT, Puska P. Relation of serum cholesterol and triglycerides to the risk for acute myocardial infarction, cerebral stroke and death in Eastern Finnish male population. Int J Epidemiol 1983;12:26-31.
45. Qizilbash N, Jones L, Warlow C, Mann J Fibrinogen and lipids as risk factors for transient ischaemic attacks and minor ischaemic strokes BMJ. 1990;303:605-609.
46. Lindgren A, Nilsson-Ehle P, Norrving B, Johansson BB. Plasma lipids and lipoproteins in subtypes of stroke. Acta Neurol Scand. 1992;86:572-578.
47. Noma A, Matsushita S, Komori T, et al. High and low density lipoprotein cholesterol in myocardial infarction and cerebral infarction. Atherosclerosis. 1979, 32:327-331.
48. Tilvis RS, Erkinjuntti T, Sulkava R, Farkkila M, Miettinen TA. Serum lipids and fatty acids in ischaemic strokes Am Heart J. 1987;113:615-619.
49. Pedro-Botet J, Senti M, Nogues X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23:1556-1562
50. Murai A, Tanaka T, Miyahara T, Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attacks Stroke 1981;12:167-172.
51. Adams RJ, Caroll RM, Nichols FT, et al. Plasma lipoproteins in cortical versus lacunar infarction. Stroke. 1989;20:346-354.
52. Sirton CR, Gianfranceschi G, Gritti I, Nappe S, Brambilla G, Paoletti P. Decreased high density lipoprotein-cholesterol levels in male patients with transient ischaemic attacks Atherosclerosis. 1979;32:205-211
53. Nieminen MS, Mattila KJ, Aalto-Setala K, et al. Lipoproteins and their genetic variation in sublets with and without angle-graphically verified coronary artery disease. Arterioscler Thromb. 1992;12:58-69.
54. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease Neurology 1993;43:1467-1472.
55. Mahieux F, Bailleul S, Fenelon G, Coudere R, Laruelle P, Guillard A. Prevalence of apolipoprotein E phenotypes in patients with acute ischemic stroke. Stroke 1990;21(suppl 1)115. Abstract.
56. Coudere R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24:661-664.
57. Woo J, Lau E, Lam CWK, et al. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 1991;22:203-208
58. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199-204.
59. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
60. Jurgens G, Koltrintger G. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987;37:513-515.
61. Urukami K, Takahashi K, Awaki E, et al Lp(a) lipoprotein abnormalities in cerebrovascular disease and vascular dementia. Stroke 1990;21(suppl 1):115-116. Abstract
62. Asplund K, Olsson T, Viitanen M, Dahlen G. Lp(a) in patients with acute stroke. Cerebrovasc Dis 1991;1:90-96.
63. Kasturi R, Yatsu FM, Alam R, Rogers S Restriction fragment length polymorphism of the apoprotein A-I-C-III gene cluster in control and stroke-prone white and black subjects: racial differences Stroke 1992;23:1257-1264.
64. MacCluer JW, Kammerer M. Dissecting the genetic contribution to coronary heart disease. Am J Hum Genet 1991;49 1139-1144.
65. Price WH, Kitchin AHM, Burgon PRS, Morris SW, Wenham PR, Donald PM. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet. 1989;24:1407-1411.
66. Motulsky AG. The 'new genetics' in blood and cardiovascular research: application to prevention and treatment. Circulation. 1984;70:26-30.
67. Graffagnino C, Gasecki A, Doig G, Hachinski V. The importance of family history in cerebrovascular disease. Stroke. 1994;25:1599-1604.
68. Puska P. Possibilities of a preventative approach to coronary heart disease starting in childhood Acta Paediatr Scand Suppl. 1985;318 229-233.
69. Bereson GS, Srinivasan SR, Nicklas TA, Webber LS. Cardiovascular risk factors in children and early prevention of heart disease. Clin Chem 1988;34:B115-B122
70. McCord JM. Is iron sufficiency a risk factor in ischemic heart disease? Circulation. 1991;83:1112-1114.
71. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Intern Med. 1987;107:526-545.